VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has named Raju Willener as its new chief financial officer, effective immediately. The appointment brings a veteran of international finance to the biotech firm as it seeks to advance its proprietary BiTAC(R) technology platform and expand its oncology pipeline.
Willener, who will report directly to CEO and Co-Founder Christoph Antz, Ph.D., is expected to play a pivotal role in shaping VERAXA's capital strategy and identifying strategic opportunities. His extensive background spans more than three decades in global capital markets, investment banking, corporate finance, asset management, and strategic leadership. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
The move comes at a critical time for VERAXA, which is advancing its pipeline of antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company's BiTAC(R) platform, a registered trademark of VERAXA Biotech GmbH, is based on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). With Willener's financial expertise, VERAXA aims to strengthen its position in the competitive oncology space and secure the resources needed to bring its therapies to clinical development and beyond.
This appointment is likely to be viewed positively by investors, as it signals the company's commitment to robust financial management and growth. Willener's experience in managing large investment portfolios and leading M&A transactions suggests he will bring a strategic perspective to VERAXA's financial operations, potentially opening doors to new partnerships and funding opportunities.
For more information on VERAXA Biotech and its latest updates, visit the company's newsroom at https://ibn.fm/VRXA. The full press release is available at https://nnw.fm/jcHOU.
As with all forward-looking statements, investors are reminded that actual results may differ materially from those expressed or implied in such statements due to various risks and uncertainties. These include factors beyond management's control, as detailed in the company's filings with the SEC. VERAXA undertakes no duty to update this information unless required by law.
